Dan Leonard
Stock Analyst at UBS
(3.83)
# 658
Out of 5,147 analysts
317
Total ratings
53.89%
Success rate
7.77%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $180 → $165 | $121.38 | +35.94% | 24 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Buy | $200 → $195 | $128.73 | +51.48% | 2 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $170 → $175 | $178.49 | -1.96% | 7 | Feb 25, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $20 | $23.05 | -13.23% | 8 | Feb 20, 2026 | |
| WAT Waters | Maintains: Neutral | $395 → $370 | $319.38 | +15.85% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $178.81 | +34.22% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $59.00 | +33.90% | 13 | Feb 5, 2026 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $40.11 | +7.21% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $93.90 | +17.15% | 11 | Oct 30, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $521.11 | +13.22% | 18 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 → $53 | $103.38 | -48.73% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $7.08 | +111.86% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $451.76 | -32.49% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $210.64 | +6.82% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,366.69 | -1.22% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $278.44 | +11.33% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $267.56 | +15.86% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $98.31 | +16.98% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $98.75 | +0.25% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $9.05 | +176.24% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $8.42 | +6.89% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $15.33 | +128.31% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $134.46 | +48.74% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.56 | +208.99% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $208.04 | -66.35% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $16.02 | -56.30% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $108.14 | +140.43% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $211.91 | -31.57% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.36 | +19.43% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $49.80 | +21.73% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $289.12 | +17.60% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $15.52 | +54.64% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.61 | +659.22% | 12 | Aug 14, 2019 |
Agilent Technologies
Feb 26, 2026
Maintains: Buy
Price Target: $180 → $165
Current: $121.38
Upside: +35.94%
Repligen
Feb 25, 2026
Maintains: Buy
Price Target: $200 → $195
Current: $128.73
Upside: +51.48%
Charles River Laboratories International
Feb 25, 2026
Maintains: Neutral
Price Target: $170 → $175
Current: $178.49
Upside: -1.96%
10x Genomics
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $20
Current: $23.05
Upside: -13.23%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $319.38
Upside: +15.85%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $178.81
Upside: +34.22%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $59.00
Upside: +33.90%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $40.11
Upside: +7.21%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $93.90
Upside: +17.15%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $521.11
Upside: +13.22%
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $103.38
Upside: -48.73%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $7.08
Upside: +111.86%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $451.76
Upside: -32.49%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $210.64
Upside: +6.82%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,366.69
Upside: -1.22%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $278.44
Upside: +11.33%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $267.56
Upside: +15.86%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $98.31
Upside: +16.98%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $98.75
Upside: +0.25%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $9.05
Upside: +176.24%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $8.42
Upside: +6.89%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $15.33
Upside: +128.31%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $134.46
Upside: +48.74%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.56
Upside: +208.99%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $208.04
Upside: -66.35%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $16.02
Upside: -56.30%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $108.14
Upside: +140.43%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $211.91
Upside: -31.57%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.36
Upside: +19.43%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $49.80
Upside: +21.73%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $289.12
Upside: +17.60%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $15.52
Upside: +54.64%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.61
Upside: +659.22%